Semaglutide GLP-1 Vial
← All Semaglutide GLP-1 research
Semaglutide (CAS 910463-68-2) is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that has been the subject of multiple large-scale, peer-reviewed randomized controlled trials published in The New England Journal of Medicine, including investigations of body weight, energy intake, and cardiovascular outcomes in adult human participants.
Research goals: Metabolic & Weight
Description
Semaglutide (CAS 910463-68-2) is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that has been the subject of multiple large-scale, peer-reviewed randomized controlled trials published in The New England Journal of Medicine, including investigations of body weight, energy intake, and cardiovascular outcomes in adult human participants.
In one such trial — the 68-week STEP 1 study — adults receiving once-weekly subcutaneous semaglutide 2.4 mg demonstrated a mean body weight reduction of 14.9%, compared with 2.4% in the placebo group [1].
Published Research on Semaglutide
The following peer-reviewed studies are summarized below. Full citations and direct links to each publication appear in the References section. All studies described in this section were conducted in adult human participants.
STEP 1 Trial — Wilding et al., New England Journal of Medicine (2021)
Wilding and colleagues conducted the Semaglutide Treatment Effect in People with Obesity (STEP 1) trial: a 68-week, double-blind, randomized, placebo-controlled phase 3 trial conducted at 129 sites across 16 countries. The trial enrolled 1,961 adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity, excluding individuals with type 2 diabetes. Participants were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, both administered alongside lifestyle intervention.
The authors reported that the treatment produced substantial, sustained, clinically relevant mean weight loss of 14.9%
, with 86% of treated participants attaining at least 5% weight loss [1]. The estimated treatment difference between semaglutide and placebo was 12.4 percentage points (95% CI, −13.4 to −11.5; P < .001), and approximately half of treated participants (50.5%) achieved a weight reduction of 15% or greater, compared with 4.9% in the placebo group.
Read the full study: Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM 2021).
SELECT Trial — Lincoff et al., New England Journal of Medicine (2023)
Lincoff and colleagues conducted the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial: a multicenter, double-blind, randomized, placebo-controlled phase 3 trial conducted at 804 clinical sites across 41 countries. The trial enrolled 17,604 adults aged 45 years or older who had a body mass index of 27 kg/m² or greater and established cardiovascular disease, but who did not have type 2 diabetes. Participants were randomized to receive once-weekly subcutaneous semaglutide 2.4 mg or placebo over a mean follow-up period of 39.8 months.
The authors concluded that weekly subcutaneous semaglutide at a amount of 2.4 mg was superior to placebo
in reducing the incidence of a composite primary endpoint comprising cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [2].
Read the full study: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (NEJM 2023).
SUSTAIN-6 Trial — Marso et al., New England Journal of Medicine (2016)
Marso and colleagues conducted the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6): a randomized, double-blind, placebo-controlled, parallel-group trial conducted at 230 sites in 20 countries. The trial randomly assigned 3,297 patients with type 2 diabetes and elevated cardiovascular risk to receive once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) or volume-matched placebo over a 104-week treatment period.
The authors observed fewer first major adverse cardiovascular events with semaglutide vs. placebo
, with a hazard ratio of 0.74 (95% CI, 0.58 to 0.95) for the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke [3]. Results met the prespecified criteria for non-inferiority, and a post hoc analysis demonstrated statistical superiority over placebo.
Read the full study: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (NEJM 2016).
Mechanism of Action — Friedrichsen et al., Diabetes, Obesity and Metabolism (2021)
To investigate the mechanism underlying weight-related findings observed in larger trials, Friedrichsen and colleagues conducted a single-center, double-blind, parallel-group, randomized phase 1 trial. The 20-week study enrolled 72 adults with obesity, who were randomized to once-weekly subcutaneous semaglutide 2.4 mg or placebo. Investigators measured ad libitum energy intake, participant-reported appetite ratings, scores on the Control of Eating Questionnaire, food cravings, and gastric emptying (assessed indirectly via paracetamol absorption).
The authors concluded that, in adults with obesity, semaglutide 2.4 mg suppressed appetite, improved control of eating, and reduced food cravings
, ad libitum energy intake, and body weight when compared with placebo [4]. No evidence of delayed gastric emptying was observed at week 20.
Read the full study: The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults with Obesity (Diabetes, Obesity and Metabolism, 2021).
About the Compound
Semaglutide is a synthetic peptide structurally analogous to native human glucagon-like peptide-1 (GLP-1), with approximately 94% amino acid sequence homology. Two structural modifications differentiate semaglutide from native GLP-1: at position 8, the alanine residue is replaced with 2-aminoisobutyric acid (Aib), and at position 34, lysine is substituted with arginine. A C-18 fatty diacid chain is attached via a γ-glutamic acid spacer. These modifications confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and enable strong, reversible binding to serum albumin, producing a circulatory half-life of approximately seven days.
- CAS Number: 910463-68-2
- Molecular Formula: C187H291N45O59
- Molecular Weight: 4113.58 g/mol
- Synonyms: NN9535, Semaglutide GLP-1
- Receptor target (in research literature): GLP-1 receptor
Product Specifications
Omnix Peptides supplies semaglutide as a sterile, lyophilized (freeze-dried) powder in a sealed glass vial intended exclusively for in vitro laboratory research. Each production lot is independently characterized using high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC–MS) protocols.
- Regulatory status (as of publication): FDA-approved as Ozempic® (2017) and Rybelsus® (2019) for type 2 diabetes, and as Wegovy® (2021) for chronic weight management; EMA-approved in equivalent indications.
- Format: Lyophilized powder
- Available strengths: 5 mg · 10 mg · 15 mg · 20 mg · 30 mg per vial
- Verified Purity: >99% (HPLC, LC–MS)
- Container: Sterile, sealed glass vial
- Documentation: Batch-specific Certificate of Analysis (COA) available
Storage, handling, intended-use, and regulatory information are provided in the corresponding tabs on this product page.
References
- Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. doi:10.1111/dom.14280
Preparation and storage
Research-only handling information. Semaglutide GLP-1 is sold strictly for in vitro laboratory research. The handling and storage guidance below reflects standard practice in published peptide research literature. Semaglutide GLP-1 is not a drug, supplement, or food product, and is not for human consumption, veterinary use, or medical applications.
Format
- Form: Vial
- Available strengths: 5mg · 10mg · 15mg · 20mg · 30mg
- Verified purity: >99% (HPLC, LC–MS)
- Documentation: Batch-specific Certificate of Analysis (COA) included
Reconstitution for Research Use
Semaglutide GLP-1 is supplied as a sterile, lyophilized powder. Reconstitution with bacteriostatic water (BAC water) is the standard preparation step used in published research protocols. The volume of BAC water used determines the final concentration of the reconstituted solution.
Example (for a 5mg vial reconstituted in 2 mL of BAC water):
- Total peptide: 5mg
- BAC water added: 2 mL
- Resulting concentration: ~2.5 mg/mL
Recommended practice:
- Use sterile bacteriostatic water (0.9% benzyl alcohol) for reconstitution; this preserves the solution for multi-week handling in laboratory settings.
- Allow the lyophilized powder to reach room temperature before opening the vial.
- Inject the BAC water against the inside wall of the vial — do not aim the stream directly at the lyophilized cake.
- Gently swirl the vial until the powder is fully dissolved. Do not shake.
- Once reconstituted, store the vial under refrigeration at 4 °C (39 °F).
Storage & Handling
- Upon receipt: Keep peptides cold and away from light.
- Lyophilized (unreconstituted): Stable at room temperature for several weeks; refrigeration at 4 °C (39 °F) is acceptable for short-term storage (days to weeks).
- Long-term storage (months to years): Freeze the lyophilized vial at −80 °C (−112 °F). Freezing optimally preserves peptide stability for extended periods.
- Reconstituted solution: Refrigerate at 4 °C (39 °F). Avoid freeze/thaw cycles, which can degrade peptide structure.
- Light exposure: Minimize exposure to direct light during handling; light can accelerate peptide degradation.
- Heat exposure: Do not leave the vial at room temperature longer than necessary for handling.
Important Notice
All Omnix Peptides products are sold for laboratory, research, or analytical purposes only. They are not for human consumption, veterinary use, or medical applications. Researchers and laboratory professionals must follow all applicable institutional, local, state, and federal regulations governing the handling of research compounds.
Citations
Citations and reference data. Omnix Peptides supplies research-grade compounds for use by qualified laboratory professionals. The references below cite published preclinical research conducted in animal models and in vitro systems. They are not intended to represent clinical evidence in humans, and Semaglutide GLP-1 has not been approved by the FDA, EMA, or any other regulatory authority for any indication.
Compound Reference Data
- Compound: Semaglutide GLP-1
- CAS Number: 910463-68-2
- Molecular Formula: C187H291N45O59
- Molecular Weight: 4113.58 g/mol
- Sequence: —
- Synonyms: NN9535, Semaglutide GLP-1
Selected Published Studies
The following peer-reviewed studies were conducted using animal models or in vitro cell-culture systems. They are listed here as a reference for researchers investigating Semaglutide GLP-1. None of these studies should be interpreted as recommending Semaglutide GLP-1 for human use, treatment, or any clinical purpose.
- Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. doi:10.1111/dom.14280
Evidence-Base Disclosure
The published evidence base for Semaglutide GLP-1 consists predominantly of preclinical research — animal models (often rats or mice) and in vitro cell-culture experiments. Where Phase I or Phase II human trials exist, they are noted in the compound page summary. Researchers should interpret the cited literature within the experimental context of each individual study.
Frequently asked questions
Frequently asked questions about the Semaglutide GLP-1 Vial. Questions on this page cover handling, storage, documentation, and ordering. Semaglutide GLP-1 is sold for laboratory, research, or analytical purposes only — not for human consumption, veterinary use, or medical applications.
How is the Semaglutide GLP-1 Vial prepared for laboratory research?
The Semaglutide GLP-1 Vial is supplied as a sterile, lyophilized (freeze-dried) powder. The standard preparation step described in published peptide research literature is reconstitution with bacteriostatic water (BAC water). The volume of BAC water used determines the final concentration of the solution. See the Amount & Handling tab for a worked reconstitution example.
Why is Semaglutide GLP-1 supplied as a lyophilized powder rather than a pre-mixed solution?
Lyophilization (freeze-drying) is the standard format for research-grade peptides because it maximizes long-term stability. A lyophilized vial stored cold and away from light remains stable for substantially longer than a pre-mixed solution. Reconstitution by the researcher also allows control over the final solution concentration.
Can the reconstituted Semaglutide GLP-1 solution be frozen?
Freeze/thaw cycles can degrade peptide structure and should generally be avoided. Reconstituted Semaglutide GLP-1 should be stored under refrigeration at 4 °C (39 °F) and used within the active research timeframe described in the Amount & Handling tab. For long-term storage, keep the vial lyophilized and freeze at −80 °C (−112 °F) until use.
Is Semaglutide GLP-1 approved by the FDA?
No. Semaglutide GLP-1 is not approved by the FDA, EMA, or any other regulatory authority for any indication. Semaglutide GLP-1 is sold by Omnix Peptides strictly for laboratory, research, or analytical purposes. It is not for human consumption, veterinary use, or medical applications.
What is included with each Semaglutide GLP-1 Vial?
Each order includes the sealed product container and a batch-specific Certificate of Analysis (COA) verifying identity and purity by HPLC and LC–MS. The full COA library for Omnix Peptides is available at /coa-lab-reports/.
What is a Certificate of Analysis (COA), and how do I read it?
A COA is a batch-specific lab report that documents the identity, purity, and quality control results for the production lot you receive. The COA lists the compound name, CAS number, lot number, analytical methods used (HPLC, LC–MS), and the measured purity percentage. Every Omnix order includes the COA for the lot shipped.
What is the CAS number for Semaglutide GLP-1?
The CAS number for Semaglutide GLP-1 is 910463-68-2. Researchers can use this identifier to locate published literature in PubMed and other scientific databases.
How does Omnix Peptides ship orders?
Orders ship from a US-based facility with tracked domestic shipping. Free shipping is offered on orders over $99. Lyophilized vials and capsules ship at ambient temperature; sprays ship insulated when seasonal conditions require it. Tracking information is provided by email after the order ships.
What if my product arrives damaged or the seal is broken?
Contact Omnix Peptides within 48 hours of delivery. Product damaged in transit or arriving with a compromised seal will be replaced at no cost. See the Shipping & Return Policy at /shipping-return-policy/ for full terms.
Where can I find published research on Semaglutide GLP-1?
Peer-reviewed studies relevant to Semaglutide GLP-1 are listed in the Citations tab on this product page. The same studies can be located independently on PubMed using the CAS number (910463-68-2) or the compound name.
Customer reviews
Certificate of Analysis
Third-party HPLC purity analysis performed by an independent laboratory for this batch.
Reviews
There are no reviews yet.